6-chloro-N-(7-methoxy-3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)imidazo[2,1-b]thiazole-5-sulfonamide | 1106976-64-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-chloro-N-(7-methoxy-3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-5-yl)imidazo[2,1-b]thiazole-5-sulfonamide
• 英文别名: 6-chloro-N-[7-methoxy-3-(2-pyrrolidin-1-ylethyl)-1H-indol-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide
• CAS: 1106976-64-0
• 化学式: C₂₀H₂₂ClN₅O₃S₂
• 分子量: 480.011
• InChiKey: KHDGGTRJVXTPMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS<br/>[FR] COMPOSES D'INDOLE SUBSTITUES ET UTILISATION DE CEUX-CI COMME MODULATEURS DES RECEPTEURS 5-HT6
  申请人：ESTEVE LABOR DR

  公开号：WO2006024535A1

  公开（公告）日：2006-03-09

  The present invention relates to substituted indole compound of general formula I, a process for their preparation, medicaments comprising substituted indole compounds as well as the use of substituted indole compounds for the preparation of medicaments, which are suitable e.g. for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT6 receptors.

  本发明涉及通式I的取代吲哚化合物，其制备方法，包含取代吲哚化合物的药物，以及利用取代吲哚化合物制备药物，该药物适用于预防和/或治疗至少部分通过5-HT6受体介导的紊乱或疾病。
• SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS
  申请人：Merce Vidal Ramon

  公开号：US20070213326A1

  公开（公告）日：2007-09-13

  The present invention relates to substituted indole compound of general formula I, a process for their preparation, medicaments comprising substituted indole compounds as well as the use of substituted indole compounds for the preparation of medicaments, which are suitable e.g. for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT 6 receptors.

  本发明涉及通式I的取代吲哚化合物、其制备方法、含有取代吲哚化合物的药物以及利用取代吲哚化合物制备药物的用途，其中所述药物适用于预防和/或治疗至少部分通过5-HT6受体介导的紊乱或疾病。
• Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1902733A1

  公开（公告）日：2008-03-26

  The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种由至少一种具有 5-HT6 受体亲和力的化合物和至少一种 NMDA 受体配体组成的活性物质组合、一种包含所述活性物质组合的药物，以及使用所述活性物质组合制造药物。
• 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP2018861A1

  公开（公告）日：2009-01-28

  The present invention relates to the use of Compounds binding to the 5HT6 receptor such as sulfonamide compounds of formula I in the manufacture of a medicament for the treatment of weight gain, obesity or associated cardio-metabolic risk factors induced by a therapeutic drug. wherein --Z either represents =C(R10) or -CH2 or =N; and wherein either Y represents -S(O2)-R13, while X represents R1; or X represents R1, while Y represents (CH2)n-R11 or Y represents R1, while X represents (CH2)n-R12; while one of R9a, R9b, R9c, or R9d represents N(R3)-S(O2)-A, or N-(S(O2)-A)2.

  本发明涉及与 5HT6 受体结合的化合物如式 I 的磺酰胺化合物在制造治疗药物中的用途，该药物用于治疗由治疗药物诱发的体重增加、肥胖或相关的心血管代谢危险因素。 其中 --Z代表=C(R10)或-CH2或=N； 其中 或者 Y 代表 -S(O2)-R13，而 X 代表 R1； 或 X 代表 R1，而 Y 代表 ( )n-R11 或 Y 代表 R1，而 X 代表 ( )n-R12； 同时 R9a、R9b、R9c 或 R9d 中的一个代表 N(R3)-S(O2)-A，或 N-(S(O2)-A)2。
• Combination of at least two 5-HT6-Ligands
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP2020230A1

  公开（公告）日：2009-02-04

  The present invention relates to a Combination of at least two 5HT6- Ligands of which one is a partial or agonist while the other is a full antagonist or an inverse agonist, a medicament comprising this comination, the use of the combiantion in the manufacture of a medicament for the treatment of memory disorders ADHD, and methods of treatment using the combination or its members.

  本发明涉及至少两种5HT6-配体（其中一种为部分或激动剂，另一种为完全拮抗剂或反向激动剂）的组合物、包含该组合物的药物、使用该组合物制造治疗记忆障碍多动症的药物，以及使用该组合物或其成员进行治疗的方法。